Neuralstem, Inc. Press Releases

CUR 
$2.7
*  
0.07
2.66%
Get CUR Alerts
*Delayed - data as of Dec. 24, 2014  -  Find a broker to begin trading CUR now
Exchange: AMEX
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Neuralstem NSI-189 Phase Ib Major Depression Disorder Neurogenic Biomarker Data Presented At The CNS Summit
11/17/2014 9:02:00 AM - PR Newswire


Neuralstem Announces Publication Of Long Term Cell Survival From Phase I NSI-566 ALS Study In The Journal "Annals Of Clinical And Translational Neurology"
11/10/2014 9:00:00 AM - PR Newswire
▲0.75 % Price Change since this news event. The Volume Ratio is 1.78.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Neuralstem Reports Third Quarter Financial Results And Provides Business And Clinical Update
11/7/2014 9:00:00 AM - PR Newswire
▲3.45 % Price Change since this news event. The Volume Ratio is 1.63.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Diagnocure Reports on Corporate Initiatives for 2014
10/30/2014 5:01:00 PM - PR Newswire


Neuralstem Alzheimer's Disease Animal Data Presented At The Congress Of Neurological Surgeons Annual Meeting
10/23/2014 9:15:00 AM - PR Newswire
▲5.88 % Price Change since this news event. The Volume Ratio is 0.8.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


First Patient Treated In Neuralstem Phase I Spinal Cord Injury Stem Cell Trial Through The UC San Diego Sanford Stem Cell Clinical Center
10/9/2014 9:15:00 AM - PR Newswire
▼-15.89 % Price Change since this news event. The Volume Ratio is 1.19.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day